medopd

Medicine OPD Scoring System β€” pharmaadvance.in
πŸ₯

Medicine OPD Scoring System

pharmaadvance.in Β· 55+ Validated Clinical Tools

❀️

Cardiovascular

7 tools
🩺
CHAβ‚‚DSβ‚‚-VAScStroke risk in Non-valvular AF
⭐ Standard0–9
β–Ύ
β€”/ 9
πŸ“‹ Prescription-Ready
🩸
HAS-BLEDBleeding risk in AF on anticoagulation
0–9Bleed Risk
β–Ύ
β€”/ 9
πŸ“‹ Prescription-Ready
🦡
Wells DVT ScorePre-test probability for Deep Vein Thrombosis
βˆ’2 to +9
β–Ύ
β€”points
πŸ“‹ Prescription-Ready
πŸ’“
HEART ScoreChest pain β€” MACE risk stratification
0–10
β–Ύ
β€”/ 10
πŸ“‹ Prescription-Ready
πŸ«€
NYHA ClassificationHeart failure functional class
Class I–IV
β–Ύ
INo limitation β€” ordinary activity does not cause symptoms
IISlight limitation β€” comfortable at rest, symptoms with moderate exertion
IIIMarked limitation β€” comfortable at rest, symptoms with minimal exertion
IVSymptoms at rest β€” unable to carry on any activity without discomfort
β€”
πŸ“‹ Prescription-Ready
πŸ₯
Revised Cardiac Risk Index (Lee)Perioperative cardiac risk
0–6
β–Ύ
β€”/ 6
πŸ“‹ Prescription-Ready
πŸ’‰
BP Classification (ACC/AHA 2017)Hypertension staging
mmHg
β–Ύ
β€”
πŸ“‹ Prescription-Ready
🫁

Respiratory

5 tools
🫁
CURB-65Community-acquired pneumonia severity
⭐ Standard0–5
β–Ύ
β€”/ 5
πŸ“‹ Prescription-Ready
πŸ’¨
mMRC Dyspnoea ScaleBreathlessness grade β€” COPD / ILD
Grade 0–4
β–Ύ
0Breathless only during strenuous exercise
1Short of breath when hurrying on level ground or up a slight hill
2Walks slower than people of same age, or stops for breath after ~1 mile
3Stops for breath after 100m or after a few minutes on level ground
4Too breathless to leave house, or breathless when dressing/undressing
β€”mMRC
πŸ“‹ Prescription-Ready
πŸ“Š
CAT Score (COPD Assessment Test)Symptom impact score
0–40COPD
β–Ύ

Rate each 0 (no problem) to 5 (worst):

β€”/ 40
πŸ“‹ Prescription-Ready
🌬️
Asthma Control Test (ACT)Asthma symptom control β€” last 4 weeks
5–25
β–Ύ

Rate each (5=never/not at all β†’ 1=all the time/extremely):

β€”/ 25
πŸ“‹ Prescription-Ready
😴
STOP-BANGObstructive Sleep Apnoea risk screening
0–8OSA
β–Ύ
β€”/ 8
πŸ“‹ Prescription-Ready
πŸ«€

Hepatology

5 tools
🏷️
Child-Pugh ScoreCirrhosis severity and surgical risk
⭐ StandardClass A/B/C
β–Ύ
β€”/ 15
πŸ“‹ Prescription-Ready
πŸ“
MELD ScoreModel for End-stage Liver Disease
6–40Transplant
β–Ύ
Capped at 4.0; if dialysis use 4.0
β€”MELD
πŸ“‹ Prescription-Ready
πŸ§‚
MELD-Na ScoreMELD incorporating sodium
Na-adjusted
β–Ύ
Range used: 125–137 mEq/L
β€”MELD-Na
πŸ“‹ Prescription-Ready
πŸ”¬
FIB-4 IndexNon-invasive liver fibrosis screening
NAFLD/Viral
β–Ύ

Formula: (Age Γ— AST) Γ· (Platelets Γ— √ALT)

β€”FIB-4
πŸ“‹ Prescription-Ready
πŸ“ˆ
APRI ScoreAST-to-Platelet Ratio Index β€” fibrosis
Cirrhosis
β–Ύ
β€”APRI
πŸ“‹ Prescription-Ready
🫘

Nephrology

4 tools
πŸ”¬
eGFR (MDRD Formula)Estimated GFR and CKD staging
⭐ StandardmL/min/1.73m²
β–Ύ
β€”mL/min/1.73mΒ²
πŸ“‹ Prescription-Ready
πŸ’Š
Cockcroft-Gault CrClCreatinine clearance β€” drug dosing
Drug dosing
β–Ύ
β€”mL/min
πŸ“‹ Prescription-Ready
πŸ§ͺ
FENa β€” Fractional Excretion of SodiumPre-renal vs intrinsic AKI
AKI
β–Ύ
β€”%
πŸ“‹ Prescription-Ready
πŸ“‹
CKD Staging (KDIGO 2012)GFR + Albuminuria staging
G1–G5 / A1–A3
β–Ύ
β€”
πŸ“‹ Prescription-Ready
🩸

Diabetes & Endocrine

4 tools
🩺
HbA1c InterpretationGlycated haemoglobin β†’ average glucose
ADA 2024
β–Ύ
β€”mmol/mol
πŸ“‹ Prescription-Ready
βš–οΈ
BMI & Obesity ClassificationWHO + Asia-Pacific thresholds
kg/mΒ²
β–Ύ
β€”kg/mΒ²
πŸ“‹ Prescription-Ready
⚠️
FINDRISCFinnish Diabetes Risk Score
0–26T2DM screening
β–Ύ
β€”/ 26
πŸ“‹ Prescription-Ready
πŸ“Š
HOMA-IRInsulin resistance assessment
Insulin resistance
β–Ύ
β€”HOMA-IR
πŸ“‹ Prescription-Ready
🦴

Rheumatology

4 tools
πŸ”΄
DAS28-CRPDisease Activity Score β€” RA
⭐ StandardRA
β–Ύ
β€”DAS28
πŸ“‹ Prescription-Ready
πŸ”΅
DAS28-ESRDisease Activity Score with ESR
RA
β–Ύ
β€”DAS28
πŸ“‹ Prescription-Ready
πŸ“‹
CDAIClinical Disease Activity Index β€” no labs required
0–76No labs
β–Ύ
β€”/ 76
πŸ“‹ Prescription-Ready
🦴
BASDAIAnkylosing Spondylitis Disease Activity
0–10AS/AxSpA
β–Ύ

Rate each 0 (none) to 10 (very severe) β€” last week:

β€”/ 10
πŸ“‹ Prescription-Ready
🧠

Neurology

4 tools
β™Ώ
Modified Rankin Scale (mRS)Disability after stroke/neurological disease
⭐ Standard0–6
β–Ύ
0No symptoms
1No significant disability β€” able to carry out usual activities
2Slight disability β€” unable to carry out all previous activities, looks after self
3Moderate disability β€” requires some help, but able to walk unassisted
4Moderately severe β€” unable to walk and attend to bodily needs without help
5Severe disability β€” bedridden, incontinent, requires constant care
6Dead
β€”mRS
πŸ“‹ Prescription-Ready
⚑
ABCDΒ² Score2-day stroke risk after TIA
TIA urgent0–7
β–Ύ
β€”/ 7
πŸ“‹ Prescription-Ready
πŸ€•
MIDASMigraine Disability Assessment Score
Migraine
β–Ύ

Days lost / productivity reduced β‰₯50% in past 3 months:

β€”MIDAS
πŸ“‹ Prescription-Ready
🧩
MMSE β€” Score Entry & InterpretationMini Mental State Examination
0–30Cognition
β–Ύ

Administer the validated MMSE form; enter total score here for interpretation and prescription output.

β€”/ 30
πŸ“‹ Prescription-Ready
πŸ‘΄

Geriatric Medicine

4 tools
πŸ§“
Clinical Frailty Scale (Rockwood CFS)Frailty staging
⭐ Standard1–9
β–Ύ
1Very Fit β€” robust, active, energetic
2Well β€” no active disease symptoms
3Managing Well β€” controlled conditions; limited to routine work
4Vulnerable β€” slowed down; fatigued by day
5Mildly Frail β€” limited dependence in instrumental ADLs
6Moderately Frail β€” help needed with all outside activities; some bathing help
7Severely Frail β€” completely dependent for personal care but stable
8Very Severely Frail β€” completely dependent; approaching end of life
9Terminally Ill β€” life expectancy <6 months
β€”CFS
πŸ“‹ Prescription-Ready
πŸƒ
Barthel IndexActivities of Daily Living β€” functional independence
0–100ADL
β–Ύ
β€”/ 100
πŸ“‹ Prescription-Ready
πŸ˜”
GDS-15 (Geriatric Depression Scale)Depression screening in elderly
0–15
β–Ύ

Tick each item if the criterion is met (as labelled):

β€”/ 15
πŸ“‹ Prescription-Ready
🍽️
MUSTMalnutrition Universal Screening Tool
0–6+
β–Ύ
β€”/ 6
πŸ“‹ Prescription-Ready
πŸ«ƒ

Gastroenterology

3 tools
πŸ”΄
Harvey-Bradshaw IndexCrohn's Disease Activity β€” simplified
Crohn's
β–Ύ
Complications (each = +1)
β€”HBI
πŸ“‹ Prescription-Ready
🩸
Rockall ScoreUpper GI bleed β€” rebleed and mortality risk
0–11UGIB
β–Ύ
Post-endoscopy (add if available)
β€”/ 11
πŸ“‹ Prescription-Ready
πŸ”¬
Glasgow-Blatchford ScoreUpper GI bleed β€” need for clinical intervention
0–23UGIB
β–Ύ
β€”/ 23
πŸ“‹ Prescription-Ready
⚑

Pain Assessment

2 tools
🌑️
NRS / VAS Pain ScoreNumeric Rating Scale
0–10
β–Ύ
0
β€”/ 10
πŸ“‹ Prescription-Ready
⚑
DN4Neuropathic pain screening
0–10Neuropathic
β–Ύ
Patient interview
Clinical examination
β€”/ 10
πŸ“‹ Prescription-Ready
πŸ•ŠοΈ

Palliative & Prognosis

2 tools
🚢
ECOG Performance StatusFunctional status β€” treatment eligibility
⭐ Standard0–5
β–Ύ
0Fully active β€” no restrictions
1Restricted in strenuous activity but ambulatory; light work ok
2Ambulatory >50% waking hours; self-care only, no work
3Limited self-care; confined to bed/chair >50% waking hours
4Completely disabled; no self-care; totally confined to bed/chair
5Dead
β€”ECOG
πŸ“‹ Prescription-Ready
πŸ“Š
Karnofsky Performance Scale (KPS)Functional ability 0–100
0–100%Oncology
β–Ύ
100%Normal β€” no complaints, no disease
90%Able to carry on normal activity; minor signs/symptoms
80%Normal activity with effort; some signs/symptoms
70%Cares for self; unable to carry on normal work
60%Requires occasional assistance; cares for most needs
50%Requires considerable assistance and frequent medical care
40%Disabled β€” requires special care and assistance
30%Severely disabled β€” hospitalisation indicated
20%Very sick β€” active supportive treatment necessary
10%Moribund β€” fatal processes progressing rapidly
β€”%
πŸ“‹ Prescription-Ready
🦠

Infectious Disease

2 tools
πŸ—£οΈ
Centor / McIsaac ScoreGAS pharyngitis β€” antibiotic decision
βˆ’1 to +5Sore throat
β–Ύ
β€”points
πŸ“‹ Prescription-Ready
🎯
Modified Alvarado ScoreAcute appendicitis probability
0–10Appendicitis
β–Ύ
β€”/ 10
πŸ“‹ Prescription-Ready
πŸ’Š

ADR & Pharmacovigilance

2 tools
πŸ’Š
Naranjo ScaleADR causality assessment
⭐ Standardβˆ’4 to +13
β–Ύ
β€”/ 13
πŸ“‹ Prescription-Ready
⚠️
Modified Hartwig SeverityADR severity grading
Level 1–7
β–Ύ
Level 1Mild β€” no specific treatment required, no discontinuation
Level 2Moderate β€” requires change in drug therapy, no hospitalisation
Level 3Moderate β€” requires hospitalisation
Level 4Severe β€” life-threatening, requires intensive medical treatment
Level 5Severe β€” causes permanent damage
Level 6Severe β€” contributing cause of death
Level 7Fatal β€” directly responsible for patient death
β€”
πŸ“‹ Prescription-Ready
πŸ’­

Psychiatry & Mood

3 tools
πŸ˜”
PHQ-9Patient Health Questionnaire β€” depression severity
⭐ Standard0–27
β–Ύ

Over the last 2 weeks, how often have you been bothered by each? (0=Not at all Β· 1=Several days Β· 2=More than half days Β· 3=Nearly every day)

β€”/ 27
πŸ“‹ Prescription-Ready
😰
GAD-7Generalised Anxiety Disorder scale
⭐ Standard0–21
β–Ύ

Over the last 2 weeks: (0=Not at all Β· 1=Several days Β· 2=More than half days Β· 3=Nearly every day)

β€”/ 21
πŸ“‹ Prescription-Ready
🎭
HAM-A (Hamilton Anxiety)Clinician-rated anxiety severity
0–56Clinician-rated
β–Ύ

Rate each item: 0=Absent Β· 1=Mild Β· 2=Moderate Β· 3=Severe Β· 4=Very severe

β€”/ 56
πŸ“‹ Prescription-Ready
🦴

Rheumatology β€” Extended

3 tools
πŸ”΄
SLEDAI-2KSLE Disease Activity Index β€” Lupus
⭐ StandardSLE0–105
β–Ύ

Tick if present in the last 10 days:

β€”SLEDAI-2K
πŸ“‹ Prescription-Ready
πŸ’œ
DAPSADisease Activity in PSoriatic Arthritis
0–164PsA
β–Ύ
Convert: mg/L Γ· 10 = mg/dL

DAPSA = TJC + SJC + CRP + Pain VAS + Patient Global VAS

β€”DAPSA
πŸ“‹ Prescription-Ready
🀲
HAQ-DI (Health Assessment Questionnaire)Functional disability in RA / inflammatory arthritis
0–3Functional
β–Ύ

Rate difficulty of each activity: 0=Without any difficulty Β· 1=With some difficulty Β· 2=With much difficulty Β· 3=Unable to do

β€”/ 3
πŸ“‹ Prescription-Ready
❀️

Cardiovascular β€” Extended

2 tools
🫁
Wells PE ScorePre-test probability for Pulmonary Embolism
⭐ StandardPE
β–Ύ
β€”points
πŸ“‹ Prescription-Ready
πŸ“Š
Framingham Risk Score (simplified)10-year CVD risk β€” primary prevention
10-yr riskPrimary prevention
β–Ύ
β€”%
πŸ“‹ Prescription-Ready
πŸ₯ Medicine OPD Scoring System Β· pharmaadvance.in Β· 40+ Validated Clinical Tools
Designed by Dr. Harkirat (PG) Β· Department of Pharmacology
Clinical decision support only β€” not a substitute for clinical judgement.
πŸ“‹ File ADR Report (CDSCO/PvPI) β†’
Scroll to Top